share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券

美股sec公告 ·  03/07 06:04
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 36,319 Class A shares on 03/06/2024, as per the latest filing. The shares, valued at approximately $430,671.77, were acquired through stock option exercises on various dates, with the most recent acquisition on 03/06/2024. Gibson's transactions over the past few months have involved the sale of 163,954 shares, generating gross proceeds of around $1,423,774.95. The upcoming sale is part of a plan adopted on 12/15/2022.
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 36,319 Class A shares on 03/06/2024, as per the latest filing. The shares, valued at approximately $430,671.77, were acquired through stock option exercises on various dates, with the most recent acquisition on 03/06/2024. Gibson's transactions over the past few months have involved the sale of 163,954 shares, generating gross proceeds of around $1,423,774.95. The upcoming sale is part of a plan adopted on 12/15/2022.
根據最新文件,Recursion Pharmicals, Inc.高管兼董事克里斯托弗·吉布森定於2024年6月3日出售36,319股A類股票。這些股票價值約430,671.77美元,是通過不同日期的股票期權行使收購的,最近一次收購是在2024年6月3日。吉布森在過去幾個月中的交易涉及出售163,954股股票,總收益約爲1,423,774.95美元。即將進行的銷售是2022年12月15日通過的計劃的一部分。
根據最新文件,Recursion Pharmicals, Inc.高管兼董事克里斯托弗·吉布森定於2024年6月3日出售36,319股A類股票。這些股票價值約430,671.77美元,是通過不同日期的股票期權行使收購的,最近一次收購是在2024年6月3日。吉布森在過去幾個月中的交易涉及出售163,954股股票,總收益約爲1,423,774.95美元。即將進行的銷售是2022年12月15日通過的計劃的一部分。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。